Oxybutynin - Penwest Pharmaceuticals

Drug Profile

Oxybutynin - Penwest Pharmaceuticals

Alternative Names: Cystrin; Cystrin CR; Oxybutynin ER - Penwest Pharmaceuticals

Latest Information Update: 18 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Penwest Pharmaceuticals
  • Developer Sanofi; Schering Oy
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Urinary incontinence

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 07 Aug 2003 Clinical trials in Urinary incontinence in USA (PO)
  • 07 Mar 2003 Leiras Oy has merged with Schering Oy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top